RECURRENT GLIOBLASTOMA

This early-stage study tests a new RNA-based vaccine for adults whose glioblastoma (a fast-growing brain cancer) has come back. The main goals are to see if the vaccine can be made safely and to find the best dose. About 24 participants will receive the vaccine to check for side …

This study aimed to test a treatment using a patient's own immune cells (T cells) trained to attack cancer stem cells in people with recurrent glioblastoma, a severe brain cancer. The goal was to find a safe dose and check for side effects. However, the trial was withdrawn before…

This study tests whether a combination of two immunotherapy drugs (relatlimab and nivolumab) is safer and more effective than standard chemotherapy (lomustine) for people whose glioblastoma (a type of brain cancer) has returned after initial treatment. About 184 adults with their…

This study tests a drug called ACT001 in 12 adults whose glioblastoma (a severe brain cancer) has come back after standard treatment. Only patients with a specific genetic marker (STAT3-high) are included. The goal is to see if the drug can shrink or stabilize the tumor for at le…

This early-phase trial tests whether adding mycophenolate mofetil (a drug usually used to prevent organ rejection) to standard chemotherapy and radiation can help treat glioblastoma, an aggressive brain cancer. The study involves 60 newly diagnosed or recurrent glioblastoma patie…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors more effectively. It involves 57 patients with recurrent glioblastoma, a fast-growing brain cancer. The goal is to find a safe dose and se…

This early-stage study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in adolescents and young adults with IDH1/2-mutant gliomas, a type of brain tumor. The goal is to find the safest dose and check for side effects. About 78 participants with newly diagnose…

This early-stage study tests a new treatment for people with malignant glioma that has returned or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), add a special gene to help them recognize and attack the tumor, and infuse them back. The mai…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study tests a combination of a drug (niraparib) and a device that delivers low-intensity electric fields (Tumor-Treating Fields) in 30 adults whose glioblastoma brain tumor has come back after standard treatment. The goal is to see if this approach can stop the tumor from gr…

This early-phase study tests a new treatment for glioblastoma, a serious brain cancer that has returned or not responded to standard therapy. The approach uses specially engineered immune cells (CAR T cells) designed to target and attack the tumor, combined with drugs that boost …

This early-phase study tests a new type of immune cell therapy (CAR T cells) designed to target a protein called MMP2 found on glioblastoma brain tumors that have returned or worsened. The main goals are to find the safest dose and understand side effects. About 19 participants w…

This early-phase trial tests whether adding the drug mycophenolate mofetil (MMF) to radiation therapy is safe for people with glioblastoma, an aggressive brain cancer. About 68 participants with newly diagnosed or recurrent glioblastoma will receive MMF alongside radiation. The m…

This early-phase study tests a new approach for people with high-grade gliomas (aggressive brain tumors) that have come back after previous treatment. Researchers place genetically modified neural stem cells directly into the brain tumor to make it more sensitive to the chemother…

This study tests whether combining two immune-boosting drugs (tocilizumab and atezolizumab) with precise radiation can shrink or stabilize recurrent glioblastoma, an aggressive brain cancer. About 59 adults whose tumor returned after initial treatment will receive the combination…

This study looks at whether a special MRI scan can measure blood flow changes in brain tumors (glioblastoma) that have come back. The goal is to see if these changes can predict how well the drug bevacizumab is working, just two weeks after starting treatment. About 146 adults wi…

This early-phase trial studies how two oral drugs, defactinib and VS-6766, reach glioblastoma tumors in the brain. Fourteen patients with new or recurrent glioblastoma will receive a single dose before surgery, and drug levels will be measured in tumor tissue and blood. The goal …